# Q32 Bio Inc.: financial statements, quarterly

QTTB · Nasdaq · CIK 1661998 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/qttb.md) · [Financials](/companies/qttb/financials.md) · [Filings](/companies/qttb/filings.md) · [Insiders](/companies/qttb/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/qttb/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0000950170-23-063667.md) | [0.0 d](/filings/0000950170-24-030478.md) | [0.0](/filings/0000950170-24-056273.md) | [0.0](/filings/0000950170-24-093305.md) | [0.0](/filings/0000950170-24-122785.md) | [0.0 d](/filings/0001193125-26-099339.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [7.5](/filings/0000950170-24-122785.md) | [8.3 d](/filings/0000950170-25-036823.md) | [9.8](/filings/0000950170-25-066371.md) | [13.4](/filings/0000950170-25-103530.md) | [14.3](/filings/0001193125-25-278812.md) | [10.5 d](/filings/0001193125-26-099339.md) | [7.1](/filings/0001193125-26-205021.md) | [5.2](/filings/0001193125-26-333831.md) | [3.6](/filings/0001193125-25-278812.md) | [3.3 d](/filings/0001193125-26-099339.md) | [3.2](/filings/0001193125-26-205021.md) | [4.3](/filings/0001193125-26-333831.md) |
| Operating income | $m | [(7.8)](/filings/0000950170-24-122785.md) | [(25.8) d](/filings/0000950170-25-036823.md) | [(14.8)](/filings/0000950170-25-066371.md) | [(17.9)](/filings/0000950170-25-103530.md) | [(18.8)](/filings/0001193125-25-278812.md) | [(14.5) d](/filings/0001193125-26-099339.md) | [(12.2)](/filings/0001193125-26-205021.md) | [(9.2)](/filings/0001193125-26-333831.md) | [(7.6)](/filings/0001193125-25-278812.md) | [45.9 d](/filings/0001193125-26-099339.md) | [(7.7)](/filings/0001193125-26-205021.md) | [(9.1)](/filings/0001193125-26-333831.md) |
| Income tax | $m | [(0.1)](/filings/0000950170-24-122785.md) | [0.4 d](/filings/0000950170-25-036823.md) | [0.0](/filings/0000950170-25-066371.md) | [0.0](/filings/0000950170-25-103530.md) | [0.0](/filings/0001193125-25-278812.md) | [0.0 d](/filings/0001193125-26-099339.md) | [0.0](/filings/0001193125-26-205021.md) | [0.0](/filings/0001193125-26-333831.md) | [0.0](/filings/0001193125-25-278812.md) | [0.0 d](/filings/0001193125-26-099339.md) | [0.0](/filings/0001193125-26-205021.md) | [0.0](/filings/0001193125-26-333831.md) |
| Net income | $m | [(14.0)](/filings/0000950170-24-122785.md) | [(27.1) d](/filings/0000950170-25-036823.md) | [1.0](/filings/0001193125-25-278812.md) | [(17.0)](/filings/0001193125-25-278812.md) | [(17.6)](/filings/0001193125-25-278812.md) | [(14.2) d](/filings/0001193125-26-099339.md) | [(11.0)](/filings/0001193125-26-333831.md) | [(9.5)](/filings/0001193125-26-333831.md) | [(7.4)](/filings/0001193125-25-278812.md) | [57.7 d](/filings/0001193125-26-099339.md) | [(7.6)](/filings/0001193125-26-333831.md) | [(8.9)](/filings/0001193125-26-333831.md) |
| Diluted EPS | $ per share | [(40.52)](/filings/0000950170-24-122785.md) | not reported | [(6.33)](/filings/0000950170-25-066371.md) | [(1.42)](/filings/0000950170-25-103530.md) | [(1.46)](/filings/0001193125-25-278812.md) | not reported | [(0.90)](/filings/0001193125-26-205021.md) | [(0.78)](/filings/0001193125-26-333831.md) | [(0.60)](/filings/0001193125-25-278812.md) | not reported | [(0.54)](/filings/0001193125-26-205021.md) | [(0.44)](/filings/0001193125-26-333831.md) |
| Basic EPS | $ per share | [(40.52)](/filings/0000950170-24-122785.md) | not reported | [1.03](/filings/0000950170-25-066371.md) | [(1.42)](/filings/0000950170-25-103530.md) | [(1.46)](/filings/0001193125-25-278812.md) | not reported | [(0.90)](/filings/0001193125-26-205021.md) | [(0.78)](/filings/0001193125-26-333831.md) | [(0.60)](/filings/0001193125-25-278812.md) | not reported | [(0.54)](/filings/0001193125-26-205021.md) | [(0.44)](/filings/0001193125-26-333831.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | period not labelled (2025-05-19) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [25.6](/filings/0000950170-25-036823.md) | [116](/filings/0000950170-25-066371.md) | [97.7](/filings/0000950170-25-103530.md) | [89.1](/filings/0001193125-25-278812.md) | [78.0](/filings/0001193125-26-099339.md) | [65.5](/filings/0001193125-26-205021.md) | not reported | [54.8](/filings/0001193125-26-333831.md) | [49.0](/filings/0001193125-25-278812.md) | [48.3](/filings/0001193125-26-333831.md) | [50.8](/filings/0001193125-26-205021.md) | [106](/filings/0001193125-26-333831.md) |
| Current assets | $m | [28.7](/filings/0000950170-25-036823.md) | [138](/filings/0000950170-24-056273.md) | [112](/filings/0000950170-24-093305.md) | [93.9](/filings/0000950170-24-122785.md) | [81.9](/filings/0001193125-26-099339.md) | [68.6](/filings/0000950170-25-066371.md) | not reported | [58.3](/filings/0000950170-25-103530.md) | [50.8](/filings/0001193125-25-278812.md) | [55.1](/filings/0001193125-26-333831.md) | [57.2](/filings/0001193125-26-205021.md) | [110](/filings/0001193125-26-333831.md) |
| Total assets | $m | [47.1](/filings/0000950170-25-036823.md) | [152](/filings/0000950170-24-056273.md) | [124](/filings/0000950170-24-093305.md) | [105](/filings/0000950170-24-122785.md) | [92.3](/filings/0001193125-26-099339.md) | [79.1](/filings/0000950170-25-066371.md) | not reported | [66.1](/filings/0000950170-25-103530.md) | [57.8](/filings/0001193125-25-278812.md) | [61.8](/filings/0001193125-26-333831.md) | [63.7](/filings/0001193125-26-205021.md) | [116](/filings/0001193125-26-333831.md) |
| Current liabilities | $m | [14.1](/filings/0000950170-25-036823.md) | [33.0](/filings/0000950170-24-056273.md) | [17.2](/filings/0000950170-24-093305.md) | [14.4](/filings/0000950170-24-122785.md) | [16.5](/filings/0001193125-26-099339.md) | [14.6](/filings/0000950170-25-066371.md) | not reported | [11.5](/filings/0000950170-25-103530.md) | [11.1](/filings/0001193125-25-278812.md) | [11.3](/filings/0001193125-26-333831.md) | [10.7](/filings/0001193125-26-205021.md) | [5.4](/filings/0001193125-26-333831.md) |
| Total liabilities | $m | [119](/filings/0000950170-25-036823.md) | [104](/filings/0000950170-24-056273.md) | [90.7](/filings/0000950170-24-093305.md) | [86.2](/filings/0000950170-24-122785.md) | [86.7](/filings/0001193125-26-099339.md) | [83.1](/filings/0000950170-25-066371.md) | not reported | [78.4](/filings/0000950170-25-103530.md) | [76.2](/filings/0001193125-25-278812.md) | [19.8](/filings/0001193125-26-333831.md) | [17.4](/filings/0001193125-26-205021.md) | [10.0](/filings/0001193125-26-333831.md) |
| Shareholders' equity | $m | [(183)](/filings/0001193125-26-099339.md) | [48.8](/filings/0001193125-25-278812.md) | [33.5](/filings/0001193125-25-278812.md) | [18.3](/filings/0001193125-25-278812.md) | [5.7](/filings/0001193125-26-333831.md) | [(4.0)](/filings/0001193125-26-333831.md) | [4.0](/filings/0001193125-25-278812.md) | [(12.2)](/filings/0001193125-26-333831.md) | [(18.4)](/filings/0001193125-25-278812.md) | [42.0](/filings/0001193125-26-333831.md) | [46.3](/filings/0001193125-26-333831.md) | [106](/filings/0001193125-26-333831.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [15.9 d](/filings/0000950170-24-122785.md) | [(10.7) d](/filings/0000950170-25-036823.md) | [(14.6)](/filings/0000950170-25-066371.md) | [(22.2) d](/filings/0000950170-25-103530.md) | [(19.5) d](/filings/0001193125-25-278812.md) | [(11.4) d](/filings/0001193125-26-099339.md) | [(12.5)](/filings/0001193125-26-205021.md) | [(10.7) d](/filings/0001193125-26-333831.md) | [(4.2) d](/filings/0001193125-25-278812.md) | [(6.2) d](/filings/0001193125-26-099339.md) | [(6.3)](/filings/0001193125-26-205021.md) | [(3.1) d](/filings/0001193125-26-333831.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-24-122785.md) | [0.0 d](/filings/0000950170-25-036823.md) | [0.0](/filings/0000950170-24-056273.md) | [0.0 d](/filings/0000950170-25-103530.md) | [0.1 d](/filings/0001193125-25-278812.md) | [0.0 d](/filings/0001193125-26-099339.md) | not reported | not reported | [0.0 d](/filings/0001193125-25-278812.md) | [0.0 d](/filings/0001193125-26-099339.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [57.4](/filings/0000950170-23-063667.md) | [0.3](/filings/0000950170-24-056273.md) | [0.3](/filings/0000950170-24-093305.md) | [0.3](/filings/0000950170-24-122785.md) | [2.3](/filings/0000950170-25-066371.md) | [12.0](/filings/0000950170-25-103530.md) | [12.1](/filings/0001193125-25-278812.md) | [12.2](/filings/0001193125-26-205021.md) | [12.2](/filings/0001193125-26-333831.md) | [12.2](/filings/0001193125-25-278812.md) | [14.1](/filings/0001193125-26-205021.md) | [20.3](/filings/0001193125-26-333831.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 29,769,466 at 2026-08-03, from the cover of the [10-Q filed 2026-08-05](/filings/0001193125-26-333831.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.